|
EIF4A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.18829999998338E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.92730000017727E-07 |
| Normal-vs-Stage2 |
2.748800E-01 |
| Normal-vs-Stage3 |
5.116400E-03 |
| Normal-vs-Stage4 |
3.91650000000077E-05 |
| Stage1-vs-Stage2 |
1.018340E-02 |
| Stage1-vs-Stage3 |
4.098500E-02 |
| Stage1-vs-Stage4 |
6.391600E-01 |
| Stage2-vs-Stage3 |
2.952600E-01 |
| Stage2-vs-Stage4 |
1.684260E-02 |
| Stage3-vs-Stage4 |
5.388000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.34939999999018E-05 |
| Normal-vs-AfricanAmerican |
8.38000000000783E-05 |
| Normal-vs-Asian |
4.15050000002193E-06 |
| Caucasian-vs-AfricanAmerican |
1.456040E-01 |
| Caucasian-vs-Asian |
1.017390E-01 |
| AfricanAmerican-vs-Asian |
8.277600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.010650E-04 |
| Normal-vs-Female |
3.27030000002448E-06 |
| Male-vs-Female |
8.928400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.15199999983773E-07 |
| Normal-vs-Age(41-60Yrs) |
8.03300000000728E-05 |
| Normal-vs-Age(61-80Yrs) |
1.009550E-02 |
| Normal-vs-Age(81-100Yrs) |
6.218400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.659500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.683900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.014390E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.166000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.723400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.826800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.313800E-01 |
| Classical-VS-Follicular |
4.700200E-02 |
| Classical-VS-Other |
6.363600E-01 |
| Classical-VS-Normal |
1.62500000011612E-07 |
| Tall-VS-Follicular |
5.983400E-01 |
| Tall-VS-Other |
3.685000E-01 |
| Tall-VS-Normal |
8.780100E-03 |
| Follicular-VS-Other |
3.255000E-01 |
| Follicular-VS-Normal |
2.541800E-02 |
| Other-VS-Normal |
1.197560E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.188200E-04 |
| Normal-vs-N1 |
7.805000E-04 |
| N0-vs-N1 |
3.607400E-01 |
|
|
